-
Ibritumomab tiuxetan (pronounced /ɪbrɪˈtuːmoʊmæb taɪˈʌksɛtæn/), sold
under the
trade name Zevalin, is a
monoclonal antibody radioimmunotherapy treatment...
- A
radioligand is a
microscopic particle which consists of a
therapeutic radioactive isotope and the cell-targeting
compound - the ligand. The
ligand is...
-
triaminopentacarboxylate scaffold for
metal ions. In
ibritumomab tiuxetan, the
chelator tiuxetan is a
modified version of DTPA
whose carbon backbone contains...
- is not
accessible in
normal cells. 131I
tositumomab and 90Y
ibritumomab tiuxetan were the
first agents of radioimmunotherapy, and they were
approved for...
- Iodine-131-sodium
iodide hyperthyroidism and
thyroid cancer Yttrium-90-ibritumomab
tiuxetan (Zevalin) and Iodine-131-tositumomab (Bexxar)
refractory lymphoma 131I-MIBG...
- such as
Yttrium Y 90-DOTA-tyr3-octreotide and
Yttrium Y 90
ibritumomab tiuxetan for the
treatment of
various cancers,
including lymphoma, leukemia, liver...
-
yttrium (Y 90)
clivatuzumab tetraxetan (USAN)
yttrium (Y 90)
ibritumomab tiuxetan (INN)
yttrium bromatum yttrium fluoratum yttrium iodide yttrium metalli****...
- methotrexate, prednisone, rituximab,
vincristine and 90Y-ibritumomab
tiuxetan.[citation needed] One
combination for
stage III/IV
relapsed or refractory...
-
radiolabeling process,
which is
tailored to the
desired product.
Ibritumomab Tiuxetan;
Zevalin - For
dosimetry estimates prior to 90Y
immunotherapy for lymphoma...
-
United States Food and Drug
Administration (FDA)
approved ibritumomab tiuxetan (Zevalin),
which is an anti-CD20
monoclonal antibody conjugated to yttrium-90...
